Gene · 54890
Papers4,144
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 4,144
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Corrigendum to "m6A hypomethylation of DNMT3B regulated by ALKBH5 promotes intervertebral disc degeneration via E4F1 deficiency". | Clin Transl Med | 2025 | 41267468 | PubTator, text mining | PubMed |
| Regulation of m6A methylation in the immune microenvironment in the development of diabetes mellitus. | J Transl Med | 2025 | 41254647 | PubTator, text mining | PubMed |
| M6A-ALKBH5-dependent RBMS3-AS3 down-regulation suppresses ferroptosis to promote lung adenocarcinoma progression through HNRNPDL/ZEB1/GPX4 axis. | NPJ Precis Oncol | 2025 | 41249383 | PubTator, text mining | PubMed |
| Examining the Roles of m6A Sites in mRNA Using the Luciferase Gene Fused With Mutated RRACH Motifs. | Bio Protoc | 2025 | 41230547 | PubTator, text mining | PubMed |
| The Epitranscriptomic Landscape of Gastric Cancer Stem Cells: The Emerging Role of m6A RNA Modifications. | Cancers (Basel) | 2025 | 41228380 | PubTator, text mining | PubMed |
| Retinal ALKBH5 inhibition induces myopia protection through selective regulation of ERK1/2 signaling. | J Transl Med | 2025 | 41225555 | PubTator, text mining | PubMed |
| Genetic variants reshape the m6A epitranscriptome and drive transcriptomic reprogramming in colorectal cancer. | Sci Rep | 2025 | 41219359 | PubTator, text mining | PubMed |
| Comprehensive Analysis of Aberrant m6A RNA Modifications Identifies Prognostic Biomarkers in Non-Small Cell Lung Cancer. | Int J Med Sci | 2025 | 41209572 | PubTator, text mining | PubMed |
| Unveiling the dynamics and therapeutic potential of m6A methyltransferases and demethylases in liver diseases. | Int J Biol Sci | 2025 | 41208876 | PubTator, text mining | PubMed |
| Editorial: Significance cytokines in immuno oncology and immunotherapy. | Transl Oncol | 2025 | 41167916 | PubTator, text mining | PubMed |
| Decreased ALKBH5 in neutrophil correlates with disease activity in rheumatoid arthritis and ALKBH5 modulates neutrophil autophagy. | Sci Rep | 2025 | 41162497 | PubTator, text mining | PubMed |
Comprehensive Explorations and Preliminary Experimental Verification of RNA Modification-Related Diagnostic Markers in the Subtype Classification of Peripheral Blood-Derived Mononuclear Cells Derived from Post-Traumatic Stress Disorder Patients. | Diseases | 2025 | 41149057 | PubTator, text mining | PubMed |
| The significance of m6A-circFOXK2 in CD4+T cells from patients with rheumatoid arthritis and circFOXK2 correlates with Th17 % and autophagy. | J Transl Autoimmun | 2025 | 41146880 | PubTator, text mining | PubMed |
| ZEB1 and ALKBH5 coregulate CRABP2 and FABP5 and jointly determine the sensitivity of anaplastic thyroid cancers to gemcitabine and retinoic acid. | NPJ Precis Oncol | 2025 | 41145842 | PubTator, text mining | PubMed |
| From intracellular drivers to immune modulators: emerging paradigms in oncogenic pathway-directed immunotherapy optimization. | Cell Commun Signal | 2025 | 41126244 | PubTator, text mining | PubMed |
| Lactylation-induced ALKBH5 targets RNF123 to worsen retinal Müller cell activation through PKM2-regulated Glycolysis in diabetic retinopathy. | J Transl Med | 2025 | 41094513 | PubTator, text mining | PubMed |
| ALKBH5 exacerbates early cardiac damage after radiotherapy for breast cancer via m6A demethylation of TLR4. | Open Life Sci | 2025 | 41079600 | PubTator, text mining | PubMed |
| The Role of m6A Modification in Regulating MSC Differentiation and Immunomodulation: Implications for Regenerative Medicine and Therapeutic Applications. | Front Biosci (Landmark Ed) | 2025 | 41074424 | PubTator, text mining | PubMed |
| Correction: ALKBH5 suppresses miR-29a-3p expression, thereby exacerbating the inflammatory response associated with spinal tuberculosis. | J Orthop Surg Res | 2025 | 41074091 | PubTator, text mining | PubMed |
| ALKBH5-IGF2BP2 axis mediates prostate cancer progression and docetaxel resistance via m6A-stabilized CLSPN RNA. | iScience | 2025 | 41069850 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/papers?page=11